Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    157
    ...
ATC Name B/G Ingredients Dosage Form Price
B02BX05 REVOLADE B Eltrombopag Olamine - 25mg 25mg Tablet, film coated 75,701,015 L.L
G04BE08 TADILAS G Tadalafil - 5mg 5mg Tablet, film coated 1,583,046 L.L
L02BG06 EXEMESTANE ARROW G Exemestane - 25mg 25mg Tablet, film coated 3,386,483 L.L
N03AX11 TOPAMAX 25 B Topiramate - 25mg 25mg Tablet, film coated 858,715 L.L
V03AC03 JADENU B Deferasirox - 180mg 180mg Tablet, film coated 27,151,164 L.L
C10AA07 ROXARDIO G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 749,058 L.L
G04BE08 TALYS G Tadalafil - 5mg 5mg Tablet, film coated 1,574,216 L.L
L01ED04 ALUNBRIG B Brigatinib - 30mg 30mg Tablet, film coated 124,685,776 L.L
M01AB16 ARACENAC G Aceclofenac - 100mg 100mg Tablet, film coated 330,585 L.L
N03AX11 TOPIRATE 25 BENTA G Topiramate - 25mg 25mg Tablet, film coated 671,921 L.L
B02BX05 REVOLADE B Eltrombopag Olamine - 50mg 50mg Tablet, film coated 151,399,262 L.L
C09CA04 ZIOREL G Irbesartan - 300mg 300mg Tablet, film coated 575,933 L.L
C10AA07 SINLIP G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 563,070 L.L
G04BE08 TYRA G Tadalafil - 5mg 5mg Tablet, film coated 3,566,558 L.L
L01ED04 ALUNBRIG B Brigatinib - 90mg 90mg Tablet, film coated 374,059,747 L.L
L02BG06 EXEMESTANE GENEPHARM G Exemestane - 25mg 25mg Tablet, film coated 1,286,662 L.L
N03AX11 TORAMAT G Topiramate - 25mg 25mg Tablet, film coated 522,755 L.L
V03AC03 DEFEROXAL 180 G Deferasirox - 180mg 180mg Tablet, film coated 13,424,141 L.L
L01ED04 ALUNBRIG B Brigatinib - 180mg 180mg Tablet, film coated 493,595,998 L.L
L02BG06 EXEMESTANE PHARMINICIO G Exemestane - 25mg 25mg Tablet, film coated 1,158,392 L.L
M01AB55 DIFEN FLEX G Diclofenac sodium - 50mg, Pridinol mesylate - 4mg Tablet, film coated 575,165 L.L
N03AX11 TOPAMAX B Topiramate - 50mg 50mg Tablet, film coated 1,914,976 L.L
V03AC03 JADENU B Deferasirox - 360mg 360mg Tablet, film coated 27,151,500 L.L
C10AA07 UBSATOR-CA G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 499,142 L.L
G04BE08 DURALIS G Tadalafil - 10mg 10mg Tablet, film coated 1,187,701 L.L
N03AX11 TOPIRAMATE ARROW G Topiramate - 50mg 50mg Tablet, film coated 765,990 L.L
P02CA03 ANDAZOL G Albendazole - 200mg 200mg Tablet, film coated 302,365 L.L
C10AA07 CRESTOR B Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 804,962 L.L
N03AX11 TOPIRATE 50 BENTA G Topiramate - 50mg 50mg Tablet, film coated 1,407,835 L.L
V03AC03 DEFEROXAL 360 G Deferasirox - 360mg 360mg Tablet, film coated 18,834,070 L.L
    ...
    157
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025